Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for tough esophageal cancer

NCT ID NCT07559045

Recruiting now Disease control Sponsor: Second Affiliated Hospital of Zunyi Medical University Source: ClinicalTrials.gov ↗

First seen May 02, 2026 · Last updated May 17, 2026 · Updated 1 time

Summary

This study tests a new treatment sequence for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either the standard treatment (chemotherapy plus radiation) or an experimental approach that starts with a combination of immunotherapy and chemotherapy, followed by radiation, and then maintenance immunotherapy. The goal is to see if the new sequence leads to better tumor shrinkage and longer time without cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Zunyi Medical University, Xinpu New District, Honghuagang District, Zunyi City, Guizhou Province

    RECRUITING

    Zunyi, Guizhou, 563000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)